Tempus AI is developing innovative AI solutions for the treatment of cancer and other diseases. Shares of Tempus AI plummeted ...

Shares of Tempus AI (NASDAQ: TEM) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the ...

Tempus AI is a healthcare-oriented artificial intelligence company. Spruce Point Capital Management released a report ...

Tempus AI Inc (NASDAQ:TEM) shares are moving higher Monday after the company introduced a new program to monitor ...

Spruce Point's short report sent Tempus AI stock down 20%. TEM shares were overvalued and risky to own even without the short ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at current levels. See why TEM is a Sell.

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Investors should exercise caution with Tempus AI stock but not be deterred from considering an investment solely based on the critical report. The stock's decline can be singularly attributed to a ...

Shares of Tempus AI, Inc. (TEM) jumped 17% on Monday morning after the company announced a new liquid biopsy assay intended ...

Shares of Tempus AI (NASDAQ: TEM) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX ...

Based on its analysis, Spruce Point stated that Tempus AI stock has the potential to fall about 50% to 60%. From the stock's closing price on Tuesday (the day before Spruce Point released its ...